Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166166 · ClinicalTrials.gov registry record · Phase 2
Endothelial Hyperpolarization in Humans
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00166166 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 174 participants.
The verdict
NCT00166166, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.
Interventions
- DRUG Acetylcholine
- DRUG Sodium nitroprusside
- DRUG Bradykinin
- DRUG Tetraethylammonium (TEA)
- DRUG L-NG-monomethyl Arginine (L-NMMA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2002-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166166
The ClinicalTrials.gov registry entry for NCT00166166 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetylcholine is the first listed.
NCT00166166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00166166 about?
NCT00166166 is a clinical study titled "Endothelial Hyperpolarization in Humans". The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.
What is the current status of trial NCT00166166?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2002-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00166166?
The interventions under investigation include: Acetylcholine (DRUG), Sodium nitroprusside (DRUG), Bradykinin (DRUG), Tetraethylammonium (TEA) (DRUG), L-NG-monomethyl Arginine (L-NMMA) (DRUG).
Who is sponsoring clinical trial NCT00166166?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.